HCV Archives – Page 15 of 29 – Treatment Action Group

HCV Pipeline: DAAs and Diagnostics in the Pangenotypic Era

July 5, 2017
Chad Cipiti

July 2017 By Annette Gaudino INTRODUCTION The continued development of direct-acting antivirals (DAAs) against hepatitis C virus (HCV) has brought both multigenotypic and pangenotypic regimens to market, with more on the horizon. These simpler-to- prescribe regimens potentially eliminate the need…

TAG Earns Coveted 4-Star Rating from Charity Navigator

June 6, 2017
Chad Cipiti

TAG’s strong financial health and commitment to accountability and transparency have earned it a 4-star rating from Charity Navigator, America’s largest independent charity evaluator.

House to People Living with HIV, HCV and TB: “Drop Dead”

May 4, 2017
Chad Cipiti

Statement condemning passage of the American Health Care Act (AHCA) today by the House of Representatives and calls for critical community action as the dangerous bill now heads to Senate.

Health Affairs Blog Post Highlights Fair Pricing Coalition Recommendations to Modernize and Strengthen Existing Laws to Control Drug Costs

March 31, 2017
Chad Cipiti

With growing bipartisan support for feasible measures to control skyrocketing prescription medication costs, a Health Affairs Blog post published today describes four proposals to strengthen and modernize cost control measures that already exist in the United States.

HIV, TB, HCV, Global Health and Research Communities Call on Congress to Protect the Fogarty International Center

March 30, 2017
Chad Cipiti

Dear Majority Leader McConnell, Minority Leader Schumer, Speaker Ryan, and Democratic Leader Pelosi: We the undersigned urge Congress to reject devastating funding cuts to the National Institutes of Health (NIH) proposed under the President’s Fiscal Year (FY) 2018 “skinny budget,” released on March 16, 2017. Of grave concern is the targeted elimination of the Fogarty International Center at NIH. This indiscriminate cut jeopardizes life-saving research required to end devastating global diseases like tuberculosis (TB) and HIV/AIDS, as well as malaria, dengue, and Ebola.

President’s Budget Blueprint Threatens Research Essential to End the Epidemics of HIV/AIDS, Tuberculosis, and Hepatitis C Virus

March 20, 2017
Chad Cipiti

TAG strongly opposses the President’s 2018 budget blueprint, which threatens research essential to ending the epidemics of HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV) in the United States and globally by cutting funding and eliminating programs.

HCV Genotypes

February 6, 2017
Chad Cipiti

February 2017 What are genotypes? A genotype is a way to put the hepatitis C virus (HCV) into categories based on similar genes. It’s important to know and understand HCV genotypes because different genotypes respond differently to medicines that treat…

Viekira XR and Technivie Fact Sheet

February 2, 2017
Chad Cipiti

Updated February 2017 The goal of hepatitis C virus (HCV) treatment is a cure (when there is no HCV in a person’s bloodstream at least 12 weeks after treatment is finished). What is Viekira XR? Viekira XR is a combination…

The Pharma Shell Game

December 12, 2016
Chad Cipiti

The global system for funding drug development socializes the costs and privatizes the pro ts though a system of taxpayer-funded research, legal corporate tax havens, and intellectual property registrations to guarantee exclusive access to markets and to reduce corporate taxes, while selling identical formulations at wildly different prices.

2016 TAG Update

December 1, 2016
Chad Cipiti

TAG's annual review of progress we've made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.